SC 13D/A: Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934
(Amendment No. 1 )*
---------

Sonus Pharmaceuticals, Inc.
--------------------------------------------------------
(Name of Issuer)

Common Stock, par value $.001 per share
--------------------------------------------------------
(Title of Class of Securities)

835692104
--------------------------------------------------------
(CUSIP Number)

Jose M. de Lasa, Abbott Laboratories, AP6D D-364, 100
Abbott Park Road, Abbott Park, Illinois 60064-3500
Tel: (847) 937-8905
--------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized
to Receive Notices and Communications)

May 14, 1996
--------------------------------------------------------
(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to
report the acquisition which is the subject of this Schedule 13D, and is
filing this schedule because of Rule 13d-1(b)(3) or (4), check the following
box / /.

Check the following box if a fee is being paid with this statement / /. (A
fee is not required only if the reporting person: (1) has a previous statement
on file reporting beneficial ownership of more than five percent of the class
of securities described in Item 1; and (2) has filed no amendment subsequent
thereto reporting beneficial ownership of five percent or less of such class.
(See Rule 13d-7.)

NOTE: Six copies of this statement, including all exhibits, should be filed
with the Commission. See Rule 13d-1(a) for other parties to whom copies are to
be sent.

*The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).


(Continued on following page(s))

Page 1 of Pages
---



CUSIP No. 835692104 13D Page of Pages
--------- --- ---

- -------------------------------------------------------------------------------
(1) Names of Reporting Persons. S.S. or I.R.S. Identification Nos. of Above
Persons

Abbott Laboratories IRS Identification Number: 36-0698440
- -------------------------------------------------------------------------------
(2) Check the Appropriate Box if a Member (a) / /
of a Group* (b) / /
- -------------------------------------------------------------------------------
(3) SEC Use Only

- -------------------------------------------------------------------------------
(4) Source of Funds*
WC
- -------------------------------------------------------------------------------
(5) Check if Disclosure of Legal Proceedings is Required Pursuant to
Items 2(d) or 2(e)
- -------------------------------------------------------------------------------
(6) Citizenship or Place of Organization
Illinois
- -------------------------------------------------------------------------------
Number of Shares (7) Sole Voting
Beneficially Owned Power 500,000
by Each Reporting --------------------------------------------------
Person With (8) Shared Voting
Power
--------------------------------------------------
(9) Sole Dispositive
Power 500,000
--------------------------------------------------
(10) Shared Dispositive
Power
- -------------------------------------------------------------------------------
(11) Aggregate Amount Beneficially Owned by Each Reporting Person
500,000
- -------------------------------------------------------------------------------
(12) Check if the Aggregate Amount in Row (11) Excludes Certain Shares*
/ /
- -------------------------------------------------------------------------------
(13) Percent of Class Represented by Amount in Row (11)
5.58%
- -------------------------------------------------------------------------------
(14) Type of Reporting Person*
CO
- -------------------------------------------------------------------------------
*SEE INSTRUCTION BEFORE FILLING OUT!





ITEM 7. MATERIAL TO BE FILED AS EXHIBITS.


A list of exhibits filed herewith is contained on the Exhibit Index
immediately preceding the exhibits and is incorporated herein by reference.


*******************************

After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.


Abbott Laboratories

DATED: September 18, 1996 By: /s/ Duane L. Burnham
-----------------------------------------
Duane L. Burnham, Chairman of the Board
and Chief Executive Officer



EXHIBIT INDEX


Exhibit Number Description Sequential Page Number
- -------------- ----------- ----------------------

Agreement between Abbott
1* Laboratories and Sonus
Pharmaceuticals, Inc.
dated May 14, 1996

2** Registration Rghts
Agreement

3** Warrant Certificate

- -------------------
* Confidential Portions omitted and filed separately with the Securities and
Exchange Commission.

** Previously filed.